Translating molecular advances in Down syndrome and Fragile X syndrome into therapies.
View/ Open
Published version
Embargoed until: 5555-01-01
Embargoed until: 5555-01-01
Volume
28
Pagination
675 - 690
DOI
10.1016/j.euroneuro.2018.03.006
Journal
Eur Neuropsychopharmacol
Issue
Metadata
Show full item recordAbstract
Ongoing treatments for genetic developmental disorders of the central nervous system are mostly symptomatic and do not correct the genetic cause. Recent identification of common mechanisms between diseases has suggested that new therapeutic targets could be applied across intellectual disabilities with potential disease-modifying properties. The European Down syndrome and other genetic developmental disorders (DSG2D) network joined basic and clinical scientists to foster this research and carry out clinical trials. Here we discuss common mechanisms between several intellectual disabilities from genetic origin including Down's and Fragile X syndromes: i) how to model these complex diseases using neuronal cells and brain organoids derived from induced pluripotent stem cells; ii) how to integrate genomic, proteomic and interactome data to help defining common mechanisms and boundaries between diseases; iii) how to target common pathways for designing clinical trials and assessing their efficacy; iv) how to bring new neuro-therapies, such as noninvasive brain stimulations and cognitive training to clinical research. The basic and translational research efforts of the last years have utterly transformed our understanding of the molecular pathology of these diseases but much is left to be done to bring them to newborn babies and children to improve their quality of life.
Authors
Faundez, V; De Toma, I; Bardoni, B; Bartesaghi, R; Nizetic, D; de la Torre, R; Cohen Kadosh, R; Herault, Y; Dierssen, M; Potier, M-CCollections
Language
Licence information
Copyright statements
Related items
Showing items related by title, author, creator and subject.
-
Differences in symptomatic and autonomic profiles in co-morbid irritable bowel syndrome and hypermobile Ehlers-Danlos Syndrome vs. irritable bowel syndrome alone
Choudhary, A; Rashed, S; Upadhyaya, A; Fikree, A; Aziz, Q (2021) -
Metabolic Syndrome in Cushing's Syndrome Patients.
Ferraù, F; Korbonits, M (2018)Cushing's syndrome (CS), including visceral obesity, dyslipidemia, hypertension and diabetes among its many manifestations, is "a model" of metabolic syndrome. Glucocorticoid (GC) excess, through a combination of effects ... -
Gastrointestinal disorders in joint hypermobility syndrome/Ehlers-Danlos syndrome hypermobility type: A review for the gastroenterologist
Beckers, AB; Keszthelyi, D; Fikree, A; Vork, L; Masclee, A; Farmer, AD; Aziz, Q (2017-08)